EcoDrugPlus

Macrophage Migration Inhibitory Factor-Like

Ensembl ID : ENSNBRG00000005547
Gene Symbol: LOC102799067
3 Cross references
229 Possible Orthologues:

Mast Cell Protease 2-Like

Ensembl ID : ENSNBRG00000023435
Gene Symbol: LOC102779201
2 Cross references
949 Possible Orthologues:

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSNBRG00000017677
Gene Symbol: MMP14B
1 Cross references
196 Possible Orthologues:

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSNBRG00000023417
Gene Symbol: LOC102783773
3 Cross references
198 Possible Orthologues:

Matrix Metalloproteinase-20-Like

Ensembl ID : ENSNBRG00000017580
Gene Symbol: LOC102787412
2 Cross references
163 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSNBRG00000020145
Gene Symbol: MTOR
1 Cross references
216 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSNBRG00000008217
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSNBRG00000001845
Gene Symbol: MC4R
1 Cross references
89 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSNBRG00000022714
Gene Symbol: LOC102792948
2 Cross references
215 Possible Orthologues:

Melatonin Receptor Type 1a-A-Like

Ensembl ID : ENSNBRG00000006898
Gene Symbol: LOC102781571
3 Cross references
186 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSNBRG00000002081
Gene Symbol: MME
4 Cross references
233 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSNBRG00000018053
Gene Symbol: LOC102790115
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).